The degree to which elderly adults experience cognitive impairments from centrally acting anticholinergic drugs is variable, but the cause of this variability is unknown. The present study examined the e4 allele as a possible modulator of the effects of trihexyphenidyl hydrochloride (Artane t ), an anticholinergic drug, on memory functioning. Of the 24 cognitively intact, elderly participants (age range 62-76), 12 who possessed the e4 allele, participated in a double-blind, randomized, placebo-controlled, crossover, three-way study. All participants were tested after receiving a single oral dose of trihexyphenidyl (1 or 2 mg) or placebo, with a 7-day washout period between sessions. Memory and psychomotor tests were administered at baseline, and at 1, 2.5, and 5 h post-treatment. Results showed that participants with the e4 allele demonstrated significant impairments in delayed recall after both 1 and 2 mg doses of trihexyphenidyl while the non-e4 group did not. Additionally, while acute administration of the 2 mg dose significantly impaired total recall in both e4 and non-e4 carriers, the e4 carriers showed a more persistent impairment. These findings held when participants with the e2 allele were excluded from the analyses. The e4 groups did not differ with respect to psychomotor performance or plasma drug levels. These results provide evidence suggesting that the e4 allele plays a significant role in increasing cognitive sensitivity to trihexyphenidyl and that a temporal component of memory consolidation may be especially vulnerable. A larger study is warranted to confirm these preliminary findings.
INTRODUCTION
Medications with central anticholinergic effects are widely prescribed in the elderly and are a common cause of adverse treatment reactions (Agostini et al, 2001) . One of the potentially debilitating side effects of these treatments is impaired cognitive functioning. In the case of a centrally acting muscarinic antagonist, trihexyphenidyl hydrochloride (Artane t ), several investigators have demonstrated memory deficits in healthy elderly volunteers in response to acute doses (Guthrie et al, 2000; Nakra et al, 1992) . For example, Nakra and co-workers reported that the administration of a single 2 mg oral dose of trihexyphenidyl was associated with significant impairments in immediate and delayed recall in cognitively intact, elderly volunteers.
Another muscarinic antagonist, scopolamine, has also been described as inducing cognitive deficits in elderly volunteers (Flicker et al, 1992; Molchan et al, 1992; Ray et al, 1992; Zemishlany and Thorne, 1991) , but with some intersubject variability unrelated to pharmacokinetic factors, such as plasma drug level (Tariot et al, 1996) . The basis for the intersubject variability in response to anticholinergic treatment is not known, but could reflect individual differences in central cholinergic function or reserve.
A viable individual difference factor associated with central cholinergic function is the APOE-e4 allele, which is considered a major genetic risk factor for sporadic and lateonset familial Alzheimer's disease (AD) (Saunders et al, 1993) . Post-mortem brain tissue samples from AD patients who are e4 carriers have shown greater reductions in choline acetyltranferase (ChAT) activity, a cholinergic marker enzyme, in the hippocampus (Poirier, 1994; Allen et al, 1997) , temporal cortex and nucleus basalis of Meynert (NBM) (Arendt et al, 1997) , and the frontal cortex (Soininen et al, 1995) . Other reports have also pointed to greater reductions in ChAT activity in AD patients homozygous for the e4 allele (e4/e4) in the hippocampus (Poirier, 1994) and the frontal cortex (Soininen et al, 1995) than AD patients who were heterozygous (ie e4/e3 or e4/e2). Further studies have provided support linking the greater cholinergic abnormalities associated with the e4 allele to reduced cholinergic repair mechanisms and plasticity. For instance, Poirier et al (1995) showed that while AD patients with and without the e4 allele had a comparable loss of cholinergic neurons in the basal forebrain, e4 carriers had greater reductions in ChAT activity in terminal projection areas (ie hippocampus, temporal cortex) than noncarriers. Furthermore, despite a 60% loss of AchE-positive neurons in the basal forebrain, ChAT activity in the hippocampus and cortex of e4 noncarrier AD subjects was relatively similar to that of e4 noncarrier controls. Similar results were reported by Arendt et al (1997) . In a post-mortem study of nondemented subjects, Allen et al (1997) showed significantly greater reductions in ChAT activity in the temporal cortex of e4 carriers compared to e4 noncarriers. To date, the relevance of these post-mortem findings to clinical populations has been limited to studies that have examined the relationship between the e4 allele and therapeutic response to cholinergic agonists in AD patients. It may be that e4 is associated with increased sensitivity to anticholinergic drug-induced cognitive toxicity, but this has not been studied directly.
These considerations provided the rationale for this controlled study to investigate the role of the e4 allele as a factor associated with the intersubject variability in cognitive deficits induced from treatment of trihexyphenidyl, a muscarinic anticholinergic agent.
METHODS

Participants
In all, 12 e4-positive and 12 e4-negative, cognitively intact, elderly adults were recruited from a pre-existing subject pool of 76 adults who previously completed a study examining the relationship between the APOE-e4 genotype and the effects of lorazepam on cognitive performance. All of the participants were community-dwelling individuals who were initially recruited through newspaper ads and flyers posted in community centers, libraries, and other public places. The e4 group consisted of two e4/e2 (two male) and 10 e4/e3 (four male and six female) participants. The e4-negative group consisted of five e3/e2 (three male and two female) and seven e3/e3 (two male and five female) participants. The groups were matched for age and education and each participant was paid $140 at the end of the study. The study was approved by the Institutional Review Board at the Nathan S Kline Institute for Psychiatric Research and all participants provided written consent and confidentiality was strictly enforced. Neither study participants nor staff involved in the psychometric and safety assessments had access to the genetic data.
Participants were free of significant neurological and medical illnesses as determined by history, physical examination, routine laboratory tests, and neuropsychological examination. Main demographic characteristics and psychometric performance at screening are listed in Table 1 . Individuals did not take medications known to affect cognitive functioning, such as neuroleptics and antidepressants, at least 2 weeks before beginning the study and had a negative urine toxicology screen. No participant met DSM-IV criteria for a psychiatric disorder and all were free of significant anxiety or depressive symptoms as determined by the Hamilton Rating Scales for Anxiety and Depression. None of the individuals had a history of psychiatric illness or treatment. Finally, all participants obtained average or better scores than gender and age-adjusted values on the Wechsler Memory ScaleFRevised General Memory Index, Wechsler Adult Intelligence ScaleFRevised (WAIS-R) Vocabulary subtest, and minimental state exam. MannWhitney U-test and w 2 tests indicated no significant differences (p40.05) between e4 and non-e4 groups on APOE-e4 and anticholinergic hypersensitivity N Pomara et al any of the demographic variables or cognitive screening measures reported in Table 1 .
Design and Procedures
The study was carried out according to a double-blind, randomized, placebo-controlled, three-way, crossover design. Following completion of the screening evaluation, individuals participated in three acute sessions, 1 week apart, during which they were administered oral doses of trihexyphenidyl (Artanet), (1 or 2 mg) or placebo. Study medications and identical placebo capsules were prepared by the hospital pharmacy. Treatment sequences were randomly assigned and balanced. Each test session began at approximately 0900 under nonfasting conditions and after obtaining a brief health history and vital signs. A battery of psychometric tests was administered just prior to (baseline) and 1, 2.5, and 5 h after treatment administration. The psychometric battery included the Buschke Selective Reminding Task (BSRT) total recall subtest, WAIS-R forward and reverse digit span tasks, the Purdue Pegboard test, and the BSRT delayed recall subtest.
APOE Genotyping
APOE genotyping was performed at the Northwest Research Laboratories at the University of Washington, using the restriction enzyme isoform genotyping method described by Hixson and Vernier (1990) .
Psychometric: Testing
The BSRT (Buschke, 1973 (Buschke, , 1974 ) was used to evaluate memory functioning during the sessions. The BSRT assesses a wide range of memory functioning and for the purposes of this report, data from the total and delayed recall components were summarized. Total recall scores reflected the sum of words correctly recalled by participants immediately after list presentation and delayed recall scores reflected the total number of words recalled after 15 min had passed since the end of the BSRT final recall phase. Full procedural details and the construction of the alternate forms used in the present study are described elsewhere (Pomara et al, 1998) . In order to normalize performance across the different versions of the BSRT, mean values for each version were computed from the placebo conditions. The highest mean value across versions was used as the numerator and the mean scores for each of the versions were used as denominators for the normalization. These simple ratio normalization values were then applied to each version across treatment conditions (Arndt et al, 1996) . The Purdue pegboard task was used to measure psychomotor functioning (Tiffin, 1968) . The task requires participants to place as many pegs as possible into a holed square palate for 30 s. Participants completed three pegboard trials that required the sole use of a dominant hand, nondominant hand, and both hands. The number of correctly inserted pegs were counted and recorded. Finally, a WAIS-R digit span task was administered at each time point to prevent rehearsal of BSRT items between the total and delayed recall tasks.
Plasma Drug Levels
Blood samples were collected before each psychometric assessment for quantitation of trihexyphenidyl plasma concentrations. Drug levels were assayed via gas chromatography using a nitrogen-specific detector.
Statistical Analyses
In these analyses, we defined treatment effects as the difference between performance following the administration of 1 or 2 mg trihexyphenidyl and performance with placebo at a particular test time point. Separate mixedmodel factorial repeated measures analyses of variance (ANOVAs) were performed on each of the outcome measures (post-treatment performance minus baseline). Separate ANOVAs were used to compare a particular trihexyphenidyl level (1 or 2 mg) to placebo, with time as a repeated variable (1, 2.5, and 5 h) and APOE allele status (e4 and non-e4) as a between subjects factor. All paired contrasts were analyzed using t-tests and a criterion of 0.025 was applied to these analyses. For the purposes of this report, the measures that were analyzed using the full model ANOVA included the BSRT total and delayed recall measures and the single-and two-hand components of the Purdue Pegboard task. One non-e4 subject had to leave a placebo testing prior to the 5 h evaluation. The missing data points were replaced with mean values for the non-e4 group 5 h placebo condition. Another non-e4 subject had an unrelated nondominant hand injury that affected motor performance during all conditions. That subject's missing data for the nondominant hand and both-hand pegboard trials were replaced with condition-appropriate mean scores from the non-e4 group.
RESULTS
Total Recall
BSRT scores for total recall are summarized in Table 2 . A main effect of treatment type indicated that compared to placebo, the 2 mg dose of trihexyphenidyl significantly reduced total recall from baseline (F (1,22) ¼ 9.17, p ¼ 0.006). The effect was significant at 1 (p ¼ 0.004) and 2.5 h (p ¼ 0.004) but not at 5 h. The effect of the 1 mg dose did not reach statistical significance (F (1,22) ¼ 0.69, p ¼ 0.415). Overall, the e4 allele status did not significantly interact with treatment type to affect total recall when placebo was compared with the 1 mg dose (F (1,22) 
However, memory impairment improved significantly from 2.5 to 5 h in the non-e4 group (p ¼ 0.012) but not in the e4 participants (p ¼ 0.17) (Figure 1 ).
Delayed Recall
Delayed recall scores from the BSRT are listed in Table 2 (Figure 2 ). Specifically, 2 mg trihexyphenidyl reduced delayed recall scores from baseline relative to placebo only in the group with the e4 allele at 2.5 h (p ¼ 0.001) and the difference in the amount of reduction at this time was significantly greater in the group with the e4 allele than the group without the e4 allele (p ¼ 0.01). The adverse effects of 2 mg trihexyphenidyl on delayed recall observed in the e4 group improved significantly between 2.5 and 5 h (p ¼ 0.020).
At the lower dose of trihexyphenidyl, a significant threeway interaction between the e4 allele status, treatment type, and time was found when reductions in delayed recall from baseline under 1 mg trihexyphenidyl were compared to placebo (F (2,44) ¼ 4.44, p ¼ 0.017) and as with the previous analyses, a significant quadratic trend was found for this interaction (F (1,22) ¼ 4.71, p ¼ 0.039). When given 1 mg trihexyphenidyl, the e4-positive group exhibited significantly greater reduction from baseline in delayed recall scores at the 2.5 h test time relative to placebo (p ¼ 0.022) and the drug-induced impairment in memory improved by 5 h (p ¼ 0.014).
A subset of individuals who were genotyped as e3/e3 (n ¼ 7) and e4/e3 (n ¼ 10) were selected for secondary analyses to determine whether observed differences in total and delayed recall associated with the e4 allele status could be attributed to the higher number of individuals in the non-e4 group who possessed the e2 allele. Eliminating the individuals with the e2 allele in both the groups did not alter the pattern of results observed in the full sample of subjects (Table 3) .
Purdue Pegboard
The question of whether the e4 allele modulated the effect of trihexyphenidyl on psychomotor performance was addressed by an examination of performance on the Purdue Pegboard. As with the memory measures, the posttreatment Purdue Pegboard data for the dominant hand, nondominant hand, and both-hand trials were transformed to change from baseline scores. Repeated measures ANOVAs comparing each drug level to placebo across time APOE-e4 and anticholinergic hypersensitivity N Pomara et al yielded no significant e4 interaction with treatment or time for the dominant hand, nondominant hand, and both-hand Purdue Pegboard trials. In addition, no treatment effects were found when repeated measures ANOVAs were carried out across treatment levels within each time for each of the e4 groups. To conclude, the analyses performed on the Purdue Pegboard measures did not produce any evidence that reactions to trihexyphenidyl during a psychomotor task varied as a function of allele status.
Order Effects
A repeated measures ANOVA that included treatment order as an additional between subjects variable indicated that treatment order did not simultaneously interact with treatment type, allele status, and time on all outcome measures.
Plasma: Drug Level
Trihexyphenidyl plasma concentrations at different time points are presented in Figure 3 . No significant differences were detected between the e4 allele groups.
DISCUSSION
The results of this study demonstrate that an acute administration of 2 mg of trihexyphenidyl produces significant impairments in total recall in both the e4 and the non-e4 participants, but this impairment improves significantly by 5 h in the non-e4 participants but not in participants who possess the e4 allele. The differences in how these groups respond to trihexyphenidyl are more marked when delayed recall is examined. While there was no significant treatment effect on delayed recall in the none4 group, the e4 participants experienced significant deficits on delayed recall following acute administrations of both 1 and 2 mg of trihexyphenidyl. These findings held when participants with the e2 allele were excluded from the analyses. In contrast to memory performance, there were no significant e4 group differences in psychomotor performance following trihexyphenidyl treatment. The differences in memory function in the e4 groups cannot be accounted for by differences in trihexyphenidyl plasma levels. In a similar study examining the relationship between allele status and response to a benzodiazepine, we observed that the e4 allele was also associated with decreased recovery of memory functions following administration of a single 1.0 mg dose of lorazepam (Pomara et al, in preparation) . More specifically, the benzodiazepine effect that differentiated between the e4 and the non-e4 groups was seen on measures of long-term memory 5 h after the treatment was administered. Thus, the decreased recovery that we observed in the e4 participants following acute administration of two classes of treatments with relatively distinct pharmacological actions is consistent with other findings and suggest that the e4 allele is associated with a general vulnerability of the brain to recover from various pharmacological and neurological insults (Alberts et al, 1995; Friedman et al, 1999; Mayeux et al, 1996; Sorbi et al, 1995) .
The cause of the increased sensitivity to the adverse effects of trihexyphenidyl in the APOE-e4 carriers is not known. One likely factor affecting variations in sensitivity to anticholinergic agents is the integrity of the central cholinergic system. It has been suggested that cognitive Figure 3 Plasma drug levels of trihexyphenidyl (ng/ml) at the times following administration.
APOE-e4 and anticholinergic hypersensitivity N Pomara et al responses to an anticholinergic challenge, such as scopolamine, reflect central cholinergic function (Ray et al, 1992; Tariot et al, 1996) . The hypersensitivity to scopolamine, which has been demonstrated in elderly participants when compared to younger participants (Flicker et al, 1992; Ray et al, 1992; Zemishlany and Thorne, 1991) and in participants with AD when compared to non-demented elderly participants (Sunderland et al, 1987) , is consistent with the well-established age-and AD-related changes in a number of markers, including reductions in the size and number of cholinergic neurons in the NBM (McGeer et al, 1984; Whitehouse et al, 1982) . Thus, the increased cognitive toxicity to trihexyphenidyl that we observed in participants with the APOE-e4 allele may reflect some form of decreased cholinergic function or reserve in this population. This hypothesis is consistent with a preliminary report in normal elderly and with the body of data derived from post-mortem studies in AD patients, briefly summarized in the introduction, linking the APOE-e4 allele to greater reductions in various cholinergic indices in specific brain regions, including the hippocampus and frontal cortex. Another possibility for the increased anticholinergic sensitivity that we observed in individuals with the e4-allele is that this group might have included individuals in the earliest stages of AD, who were not necessarily identified by the psychometric battery that was employed in the current study.
The relationship between cognitive toxicity, the role of the e4 allele, and cholinergic function is likely not simple. In contrast to earlier findings (Poirier et al, 1995) , not all subsequent investigations have found a relationship between APOE genotype and treatment response to cholinesterase inhibitors in AD (Farlow et al, 1999; Raskind et al, 2000) . Additionally, not all studies have found a relationship between the e4 allele and cholinergic abnormalities in AD (Corey-Bloom et al, 2000; Svensson et al, 1997) and related animal models (Bronfman et al, 2000) . The basis for the conflicting results in human studies is not known but could be due to methodological differences, including the brain region sampled and autopsy time intervals. Another factor is the degree to which the e4-positive and -negative AD groups were matched with respect to duration or severity of dementia, variables that could influence cholinergic indices independently of APOE polymorphisms. Some recent investigations also suggest that cholinergic abnormalities, as measured by reductions in the neocortical activity of the cholinergic marker enzymes, ChAT and AchE, may not be an early pathophysiological event in AD (Davis et al, 1999; Tiraboschi et al, 2000) . Additionally, a study in individuals with mild cognitive impairment actually found an upregulation of ChAT activity in the hippocampus and frontal cortex of this population (DeKosky et al, 2002) . It should be noted that the findings from these studies are derived from post-mortem observations. Estimates of the integrity of the cholinergic system captured in these studies are more likely to reflect a static state of the cholinergic system rather than the range of function presumably necessary for normal cognition.
It is possible that the greater sensitivity to anticholinergic toxicity in cognitively intact individuals with the e4 allele reflects abnormalities in cholinergic response to a challenge rather than the effects of altered basal cholinergic activity.
Such abnormalities may well go undetected by the static measures of central cholinergic function typically obtained in post-mortem studies. Bartus and Emerich (1999) reported significant cholinergic abnormalities in rodents, primates, and humans in the absence of any significant reduction in ChAT or AchE activity. Poirier (1994) proposed that the e4 allele may contribute to a decrease in acetylcholine synthetic capacity and decreased cholinergic synaptic plasticity even in the absence of any reductions in ChAT activity. He suggested that this could arise from previously described APOE4 isoform-specific reductions in the transport of cholesterol and phospholipids, such as phosphatidylcholine and phosphatidylethanolamine, which can serve as precursors to choline in the synthesis of acetylcholine. In animal experiments, the administration of an antimuscarinic challenge, such as the one employed in the current experiment, has been shown to be accompanied by compensatory increases in acetycholine release in various brain regions including the hippocampus (Michikawa et al, 2000; Wood and Cheney, 1979) . Thus, reductions in Ach synthetic capacity associated with the e4 allele, if confirmed, may reduce the efficiency of the central cholinergic system in overcoming a muscarinic blockade and thereby contribute to our observations. Although at this point the nature of the interaction between the cholinergic system and the e4 allele that increases cognitive toxicity is unclear, the present results suggest that the process is dynamic.
In summary, the present results, which need to be confirmed in a larger sample, suggest that the APOE-e4 allele is associated with increased sensitivity to anticholinergic treatment-induced memory deficits and a slower recovery from these impairments. Since this particular form of the APOE gene is carried by a significant number of individuals, and treatments with central anticholinergic effects are widely prescribed in the elderly, these preliminary findings, if confirmed, could have important public health implications. From the neuroscience perspective, these findings also suggest the most sensitive indices of cognitive toxicity that may be observed by examining a broader time frame of treatment response than is typically studied.
